N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,472 Comparative Effectiveness of Antibiotics for Respiratory Infections
Acute Otitis Media · Acute Sinusitis · Group A Streptococcal Pharyngitis
Primary: Health Related Quality of Life Score — 91.5; 90.2 scores on a scale — p=0.008
N/A N=194 Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department
Respiratory Tract Infections · Influenza, Human · Common Cold
Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants
N/A N=9,151 Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
Healthy
Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001
N/A N=2,401 A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
Respiratory Syncytial Virus
Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years
N/A N=82 Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus Infection
Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants
N/A N=360 Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
Viral Infection · Acute Respiratory Infection · Upper Resp Tract Infection
Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
Phase 4 N=204 Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections
Acute Respiratory Viral Infections
Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms. — 4.1; 4.5 days — p=0.032
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
N/A N=91 Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
Respiratory Syncytial Virus Infection
Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04
N/A N=421 Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections
Upper Respiratory Tract Infections
Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants
N/A N=248 Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)
Acute Respiratory Infections (ARIs)
Primary: Inappropriate Antibiotic Prescribing Rate for Qualifying Acute Respiratory Infection Diagnoses — 0.20; 0.19; 0.08; 0.09 proportion of visits
Phase 4 N=50 Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
Hematological Malignancies
Primary: Occurrences of Pneumonia — 4; 3 Participants
Phase 2 N=21 RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
Upper Respiratory Tract Infection · Lower Respiratory Tract Infection
Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change
N/A N=523 Wood Stove Interventions and Child Respiratory Health
Lower Tract Respiratory Infection
Primary: Number of Participants With at Least One LRTI During Follow-up Period — 16; 20; 17; 138 Participants — p=0.68
Phase 2 N=260 Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness
Severe Acute Respiratory Illness
Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634
Phase 2 N=38 Clinical Response to Rhinovirus Challenge
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
Phase 2 N=40 Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
RSV Bronchiolitis
Primary: IL-8 Concentrations — 12,795; 14,676 Pg/ml — p=0.6
Phase 2 N=107 Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents
Respiratory Infection
Primary: Number of Acute Respiratory Infections (ARIs) — 32; 48 events
Phase 3 N=2,810 Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections
Acute Upper Respiratory Tract Infection
Primary: Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4 — 12.96; 12.87; 12.71 units on a scale
Phase 3 N=27 Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
Sinusitis, Acute
Primary: Number of Participants With a Clinical Outcome of "Cure" at Test of Cure (TOC: Day 15) — 23; 3; 0 Participants
Phase 2 N=48 Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
N/A N=26 Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
N/A N=103 The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.
Bronchiolitis
Primary: Length of Hospital Stay — 3.5; 3.6; 4.5 days
Phase 4 N=1,107 Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Influenza · Pneumonia
Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460
N/A N=28 The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
RSV Infection
Primary: Number of Participants With Challenge-related Adverse Events — 0; 3 Participants
Phase 2 N=82 A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
Respiratory Syncytial Virus
Primary: Total Symptom Score (TSS) Area Under the Curve (AUC) — 93.64; 62.53; 73.75; 78.34 days x Score